BioSpace News Archive

Predefined Patient Retention Threshold Met: 10% Early Discontinuation Rate Due to Adverse Events Supports Expansion of Patient Enrollment

Salix Pharmaceuticals will present new scientific data, including one podium presentation and eight posters evaluating investigative data on the safety and efficacy of XIFAXAN® (rifaximin) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) at Digestive Disease Week (DDW).

Future Farm Technologies Inc. is pleased to announce that it will be presenting at the 8th annual LD Micro Invitational.

Global phase 2 study will evaluate safety and efficacy of DS-8201 in patients with unresectable and/or metastatic non-squamous HER2-overexpressing or HER2-mutated non-small cell lung cancer

Omnicell, Inc. will showcase its award-winning platform of solutions at the American Society of Health-System Pharmacists (ASHP) 2018 Summer Meetings and Exhibition.

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming release of financial results for the six months ended April 30, 2018, to take place on Thursday, June 7, 2018.

Members include experts in oncology, immunology, and drug discovery and development

Cortexyme has successfully completed key components of its phase 1 clinical development program for lead compound COR388

This small molecule agent potently suppresses DUX4 function, the molecular cause of the disease.

Mr. Irving has overseen business strategy, R&D planning, product commercialization and business development for companies of all sizes for over 35 years, with an interest in neuroscience.